We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TLSA:NASDAQTiziana Life Sciences Ltd Analysis

Data as of 2026-09-01 - not real-time

$0.97

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $0.9666, Tiziana Life Sciences Ltd shows a bearish moving-average alignment, with shorter averages beneath longer ones. The last 30 days have lost 3.3%. Relative strength is 39.3 — approaching oversold — and the MACD signal is bearish. Price has been bracketed by support at $0.9100 and resistance at $1.25.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 836.6% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 74.5%, a beta of 1.23 and a maximum drawdown of 61.1%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.

Top Market Events

Top line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled...BOSTON, June 15, 2026 GLOBE NEWSWIRE -- Tiziana Life Sciences, Ltd.BOSTON, Aug. 06, 2026 GLOBE NEWSWIRE -- Tiziana Life Sciences, Ltd. Nasdaq: TLSA 'Tiziana” or the 'Company” , a...

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 1.34
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 1.34
  • Analyst targets imply +836.6% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Analyst targets imply +836.6% versus the current price
  • Negative return on equity of -924.3%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

P/E Ratio-4.8
ROE-924.32%
ROA-115.96%
Debt/Equity876.92
Op. Cash Flow$-12847000
Free Cash Flow$-5476750
Industry P/E30.5

Technical Analysis

TrendBearish
RSI39.3
Support$0.91
Resistance$1.25
MA 20$1.06
MA 50$1.09
MA 200$1.34
MACDBearish
VolumeDecreasing
Fear & Greed Index92.93

Valuation

Target Price$9.05
Upside/Downside836.62%
GradeFair
TypeBlend

Risk Assessment

Beta1.23
Volatility74.46%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.